DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for ovarian cancer — screening already-approved drugs against its 45-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian cancer maps to a 45-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedEribulinApproved drug
Structures already discussed alongside ovarian cancer in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Tubulin-Eribulin complex — Eribulin has a real, experimentally solved structure in complex with this target (PDB 5JH7, 2.25 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet 6k9drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5JH7 · 2.25 Å · ligand Eribulin (6K9). Experimental structure, not a prediction.
What the evidence adds up to
In a phase I trial from 1997, fifteen ovarian carcinoma patients received a single intravenous infusion of the chimeric monoclonal antibody c-MOv18 at doses from 5 mg to 75 mg. No significant changes in haematological, biochemical, or urine profiles were observed. At doses of 50 mg or higher, all patients experienced side effects including fever, headache, and nausea or vomiting, but none exceeded Grade II on the WHO toxicity scale. No human anti-chimeric antibody response was detected up to twelve weeks after infusion. The mean elimination half-life was significantly longer at doses of 30–75 mg than at 1 mg, and the absolute amount of c-MOv18 found in carcinoma tissue increased with dose. The authors concluded that a single dose up to 75 mg is safe and that the antibody might be applicable as an unmodified antibody or as an immunoconjugate, but the study did not test therapeutic efficacy — it measured only safety, pharmacokinetics, and tumour localisation.
A 1981 retrospective study of 97 ovarian cancer cases diagnosed and treated at a single district general hospital between 1970 and 1980 reported improved survival figures resulting from a policy of aggressive surgery followed by multiple chemotherapy. No specific drug names, response rates, or survival durations are given in the abstract, and the data are from a small, non-randomised, single-centre series spanning a decade of changing practice.
A 2025 review article on drug repositioning for ovarian cancer describes in vitro experiments across diverse cancer cell lines and preclinical in vivo models, claiming that these insights show efficacy and potential synergies with other agents, favouring cost-effective treatments. The abstract provides no drug names, no numerical results, and no clinical data — it is a review of preclinical work only, with no human trial results reported.
A 2012 book chapter and a 2021 overview paper both summarise the molecular biology, pathogenesis, and histopathological subtypes of ovarian cancer, noting that the origin, molecular basis of carcinogenesis, and therapy options remain partially unknown. A 2017 Russian-language paper attempts to build a logically grounded model of ovarian cancer pathogenesis to reflect different clinical manifestations and guide future research. None of these three publications report any drug testing, survival data, or clinical outcomes.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
InTech eBooks · 2012 · 29 citations
Ovarian Cancer - Basic Science Perspective
AbstractWorldwide, Ovarian carcinoma continues to be responsible for more deaths than all other gynecologic malignancies combined. International leaders in the field address the critical biologic and basic science issues relevant to the disease. The book details the molecular biological aspects of ovarian cancer. It provides molecular biology techniques of understanding this cancer. The techniques are designed to determine tumor genetics, expression, and protein function, and to elucidate the genetic mechanisms by which gene and immunotherapies may be perfected. It provides an analysis of current research into aspects of malignant transformation, growth control, and metastasis. A comprehensive spectrum of topics is covered providing up to date information on scientific discoveries and management considerations.
Eribulin mesylate (halichondrin B analog E7389) in platinum‐resistant and platinum‐sensitive ovarian cancer
AbstractBACKGROUND: Eribulin mesylate is a tubulin inhibitor with activity superior to paclitaxel in NIH:OVCAR-3 human epithelial ovarian cancer xenograft models. In this study, the authors assessed the efficacy of eribulin in platinum-resistant and platinum-sensitive recurrent ovarian cancer. METHODS: Patients with recurrent, measurable epithelial ovarian cancer who had received ≤2 prior cytotoxic regimens and who had adequate organ function were enrolled into 2 separate cohorts: 1) platinum-resistant patients (who had a progression-free interval <6 months after their last platinum-based therapy) and 2) platinum-sensitive patients (who had a progression-free interval ≥6 months after their last platinum-based therapy). Eribulin 1.4 mg/m(2) was administered over 15 minutes intravenously on days 1 and 8 every 21 days. Efficacy was determined by objective response on computed tomography studies. RESULTS: In the platinum-resistant cohort, 37 patients enrolled, and 36 patients were evaluable for response and toxicity. Two patients achieved a partial response (5.5%), and 16 patients (44%) had stable disease as their best response. The median progression-free survival was 1.8 months (95% confidence interval, 1.4-2.8 months). In the platinum-sensitive cohort, 37 patients enrolled, and all were evaluable for response. Seven patients achieved a partial response (19%). The median progression-free survival was 4.1 months (95% confidence interval, 2.8-5.8 months). The major toxicity was grade 3 or 4 neutropenia (42% of platinum-resistant patients; 54% of platinum-sensitive patients). CONCLUSIONS: Eribulin produced an objective response in 5.5% of women with platinum-resistant, recurrent ovarian cancer and in 19% of women with platinum-sensitive disease. The median progression-free survival was 1.8 months in the platinum-resistant group and 4.1 months in the platinum-sensitive group.
BJOG An International Journal of Obstetrics & Gynaecology · 1981 · 9 citations
OVARIAN CANCER: THE TEN YEAR EXPERIENCE OF A DISTRICT GENERAL HOSPITAL
AbstractNinety-seven cases of ovarian cancer were diagnosed and treated at Northwick Park Hospital between 1970 and 1980. In this retrospective study data are presented about symptomatology and certain aetiological factors. The survival with different treatment regimens is compared, with particular reference to the improved figures resulting from a policy of aggressive surgery followed by multiple chemotherapy.
Frontiers in Oncology · 2025 · 7 citations · open access
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments
AbstractDrug repositioning, the practice of identifying novel applications for existing drugs beyond their originally intended medical indications, stands as a transformative strategy revolutionizing pharmaceutical productivity. In contrast to conventional drug development approaches, this innovative method has proven to be exceptionally effective. This is particularly relevant for cancer therapy, where the demand for groundbreaking treatments continues to grow. This review focuses on drug repositioning for ovarian cancer treatment, showcasing a comprehensive exploration grounded in thorough in vitro experiments across diverse cancer cell lines, which are validated through preclinical in vivo models. These insights not only shed light on the efficacy of these drugs but also expand in potential synergies with other pharmaceutical agents, favoring the development of cost-effective treatments for cancer patients.
Romanian Journal of Military Medicine · 2021 · 6 citations · open access
Ovarian cancer under the magnifying glass
AbstractCancer is a pathology generating problem to the public health systems all over the world. The etiology and pathogenesis of ovarian cancer are still partially unknown. It is still a challenge when it comes to the origin, the molecular basis of ovarian carcinogenesis, tumor progression, and therapy options of ovarian cancer. This paper brings an overview of ovarian cancer, starting with the pathogenesis, histopathological forms, and molecular biology of ovarian cancer, and follows the growth factors as molecular targets for specific therapy.
Рак яичников: новый взгляд и патогенетические варианты
AbstractRecent years, our knowledge concerning pathogenesis and molecular processes initiation that take place in different tumor subtypes, greatly multiplied. And although clinically ovarian cancer is one disease, scientists are increasingly talking about the fact that different morphological subtypes have different course and prognosis. In the present study, in terms of the array of facts an attempt to build the closest logically grounded model of ovarian cancer pathogenesis was made. It had to be able to reflect variants of ovarian cancer clinical manifestation and predetermine the most promising ways of further scientific research to solve gynecological oncology topical issues.
Bevacizumab, eribulin, and oxaliplatin in patients with platinum-resistant ovarian carcinomas: A phase II study with biomarker analysis.
Abstract5550 Background: Eribulin is a candidate for paclitaxel-refractory breast cancers, and Bevacizumab (B) is known to enhance efficacy of anti-cancer agents in ovarian cancers. A phase II study to evaluate weekly administration of B with eribulin and oxaliplatin (EriOX) in patients with platinum-resistant and refractory ovarian carcinomas (PR-ROC) was performed. Methods: Eligible patients were as follows: (a) ECOG PS = 0~2 (b) histologically confirmed epithelial ovarian cancer (c) diagnosed as platinum-resistant ovarian cancer (d) written informed consent. Patients were treated with weekly-B-EriOX consisting of B (2mg/kg), eribulin (1mg/m 2 ) and oxaliplatin (30mg/m 2 ), three weeks on and on week off, q4weeks. The study was conducted using two-stage design of Simon (type I error = 0.05, power = 0.9, true response rate = 25%). Biomarker analyses including serum VEGF, BNP, p53, IL-6, and Her-2 were also conducted. Results: A total of 34 patients were enrolled in the present study: 13 cases in the first-stage, and additional 21 cases in the second-stage. There were 3 responders (≧2) in the first-stage, and the protocol was proceeded to the second-stage. Median age of the patient was 58.5 years (range: 35-76), and median number of previous regimen was 4 (range: 2-9). Overall, two patients (6%) had a complete response (CR), 8 patients (24%) had a partial remission (PR) and 16 patients (47%) had a stable disease (SD). The response rate and clinical benefit rate (CR+PR+SD) were 29% and 76%, respectively. Median progression-free survival was 4 months (range: 1-27+). Hematological adverse effects (AE) with grade 3/4 were observed in 4 patients (11%). Non-hematological AE greater than grade2 was observed in one case: hypo albuminemia and edema, which were manageable and tolerable. As there were 10 responders (≧6), the protocol was considered for additional investigation. The Patients with elevated serum mutated p53 / IL-6 showed lower response and worse prognoses. Conclusions: Weekly B and EriOX administration was considered for additional investigation for patients with PR-ROC. Serum mutated p53 protein and/or IL-6 could be biomarkers in PR-ROC patients treated with weekly B and EriOX.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
